Table 2 Results of global and subgroup analysis
Subgroup defined by | Patient number | Antibody ch14.18 group | Maintenance chemotherapy group | No consolidation group | Log-rank p-value | |
|---|---|---|---|---|---|---|
All patients | 344 | 5yEFS | 45.2 ± 3.9% | 34.1 ± 4.8% | 33.3 ± 5.7% | .098 |
5yOS | 55.8 ± 3.9% | 42.2 ± 5.0% | 39.1 ± 5.9% | .019 | ||
9yEFS | 40.9 ± 3.8% | 31.0 ± 4.7% | 31.8 ± 5.6% | .098 | ||
9yOS | 45.8 ± 4.0% | 33.9 ± 4.8% | 34.6 ± 5.7% | .019 | ||
With ASCT | 145 | 5yEFS | 50.5 ± 4.9% | 38.1 ± 7.5% | .241 | |
5yOS | 58.3 ± 4.9% | 45.2 ± 7.7% | .152 | |||
9yEFS | 44.5 ± 4.9% | 38.1 ± 7.5% | .241 | |||
9yOS | 47.0 ± 5.0% | 40.5 ± 7.6% | .152 | |||
No ASCT | 189 | 5yEFS | 36.5 ± 6.1% | 34.1 ± 4.8% | 25.9 ± 8.4% | .133 |
5yOS | 51.9 ± 6.3% | 42.2 ± 5.0% | 29.6 ± 8.8% | .094 | ||
9yEFS | 34.9 ± 6.0% | 31.0 ± 4.7% | 21.6 ± 8.1% | .133 | ||
9yOS | 43.9 ± 6.5% | 33.9 ± 4.8% | 25.4 ± 8.5% | .094 | ||
NB90 | 177 | 5yEFS | 48.0 ± 10% | 34.1 ± 4.8% | 37.7 ± 6.7% | .300 |
5yOS | 52.0 ± 10% | 42.2 ± 5.0% | 41.5 ± 6.8% | .250 | ||
9yEFS | 44.0 ± 9.9% | 31.0 ± 4.7% | 33.6 ± 6.5% | .300 | ||
9yOS | 48.0 ± 10.0% | 33.9 ± 4.8% | 37.6 ± 6.7% | .250 | ||
NB97 | 157 | 5yEFS | 44.7 ± 4.2% | 18.8 ± 9.8% | .067 | |
5yOS | 56.5 ± 4.2% | 31.3 ± 11.6% | .050 | |||
9yEFS | 40.3 ± 4.1% | 18.8 ± 9.8% | .067 | |||
9yOS | 45.3 ± 4.3% | 23.4 ± 11.0% | .050 | |||
NB90 maintenance and NB97 ASCT+ch14.18 patients | 177 | 5yEFS | 51.3 ± 5.7% | 34.1 ± 4.8% | .106 | |
5yOS | 60.3 ± 5.5% | 42.2 ± 5.0% | .035 | |||
9yEFS | 44.7 ± 5.6% | 31.0 ± 4.7% | .106 | |||
9yOS | 46.6 ± 5.7% | 33.9 ± 4.8% | .035 | |||
MYCN not amplified | 214 | 5yEFS | 48.4 ± 4.5% | 37.0 ± 6.5% | 35.3 ± 8.2% | .166 |
5yOS | 61.9 ± 4.4% | 47.8 ± 6.5% | 44.1 ± 8.5% | .041 | ||
9yEFS | 45.2 ± 4.5% | 31.4 ± 6.3% | 35.3 ± 8.2% | .166 | ||
9yOS | 52.0 ± 4.6% | 34.9 ± 6.4% | 38.0 ± 8.4% | .041 | ||
MYCN amplified | 69 | 5yEFS | 34.2 ± 7.7% | 20.0 ± 10.3% | 31.3 ± 11.6% | .997 |
5yOS | 36.8 ± 7.8% | 26.7 ± 11.4% | 31.3 ± 11.6% | .902 | ||
9yEFS | 25.5 ± 7.2% | 20.0 ± 10.3% | 31.3 ± 11.6% | .997 | ||
9yOS | 24.9 ± 7.2% | 20.0 ± 10.3% | 31.3 ± 11.6% | .902 | ||
CR/VGPR after induction | 267 | 5yEFS | 47.0 ± 4.3% | 34.4 ± 5.3% | 36.5 ± 6.7% | .185 |
5yOS | 58.2 ± 4.3% | 37.9 ± 5.4% | 42.3 ± 6.9% | .032 | ||
9yEFS | 41.7 ± 4.3% | 30.5 ± 5.2% | 34.5 ± 6.6% | .185 | ||
9yOS | 45.8 ± 4.4% | 32.8 ± 5.3% | 36.3 ± 6.7% | .032 | ||
CR after induction | 166 | 5yEFS | 54.9 ± 5.5 % | 40.5 ± 7.1 % | 48.6 ± 8.4 % | .392 |
5yOS | 62.2 ± 5.4 % | 46.4 ± 7.2 % | 57.1 ± 8.4 % | .218 | ||
9yEFS | 49.8 ± 5.5% | 36.1 ± 6.9% | 45.7 ± 8.4% | .392 | ||
9yOS | 51.6 ± 5.6% | 37.8 ± 7.0% | 48.6 ± 8.4% | .218 | ||
PR after induction | 60 | 5yEFS | 37.0 ± 9.3% | 29.4 ± 11.1% | 25.0 ± 10.8% | .644 |
5yOS | 46.9 ± 9.8% | 58.8 ± 11.9% | 31.3 ± 11.6% | .632 | ||
9yEFS | 37.0 ± 9.3% | 29.4 ± 11.1% | 25.0 ± 10.8% | .644 | ||
9yOS | 46.9 ± 9.8% | 35.3 ± 11.6% | 31.3 ± 11.6% | .632 | ||
No residual bone marrow involvement after induction | 316 | 5yEFS | 46.8 ± 4.0 % | 36.0 ± 5.0 % | 33.8 ± 5.7 % | .122 |
5yOS | 57.0 ± 4.0 % | 43.4 ± 5.1 % | 39.7 ± 5.9 % | .033 | ||
9yEFS | 42.1 ± 4.0% | 32.6 ± 4.9% | 32.2 ± 5.6% | .122 | ||
9yOS | 46.8 ± 4.1% | 35.7 ± 5.0% | 35.1 ± 5.8% | .033 |